Literature DB >> 18752497

Activated Stat3 expression in gestational trophoblastic disease: correlation with clinicopathological parameters and apoptotic indices.

H Y Chan1, M K Y Siu, H J Zhang, E S Y Wong, H Y S Ngan, K Y K Chan, A N Y Cheung.   

Abstract

AIMS: To assess the expression profile of the activated form of signal transducer and activator of transcription (Stat)3 in gestational trophoblastic disease (GTD) and correlate the findings with clinicopathological parameters. METHODS AND
RESULTS: By immunohistochemistry, both cytoplasmic and nuclear expression of p-Stat3-Ser(727) was demonstrated in 88 trophoblastic tissues, including placentas and GTD. Nuclear immunoreactivity of p-Stat3-Ser(727) was significantly higher in hydatidiform mole (HM) (P < 0.001) and choriocarcinoma (P = 0.009) when compared with normal placentas. Placental site trophoblastic tumours (PSTT) and epithelioid trophoblastic tumours (ETT) also demonstrated higher nuclear p-Stat3-Ser(727) expression than their normal trophoblast counterparts. Higher p-Stat3-Ser(727) expression was confirmed in choriocarcinoma cell lines, JEG-3 and JAR, than in a normal trophoblast cell line, with both nuclear and cytoplasmic fractions demonstrated by immunoblotting. Spontaneously regressed HM showed significantly increased nuclear and cytoplasmic p-Stat3-Ser(727) immunoreactivity over those that developed gestational trophoblastic neoplasia (GTN) (P = 0.013, P = 0.039). There was a significant positive and inverse correlation between nuclear p-Stat3-Ser(727) immunoreactivity and apoptotic indices [terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labelling and M30 CytoDeath antibody] (P = 0.001, P < 0.001, Spearman's rho test) and Bcl-2 expression (P = 0.034), respectively.
CONCLUSIONS: p-Stat3-Ser(727) plays a role in the pathogenesis of GTD, probably through the regulation of apoptosis. p-Stat3-Ser(727) immunoreactivity is a potential marker in predicting GTN in HM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752497     DOI: 10.1111/j.1365-2559.2008.03089.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  p21-Activated kinase-1 promotes aggressive phenotype, cell proliferation, and invasion in gestational trophoblastic disease.

Authors:  Michelle K Y Siu; Matthew C W Yeung; HuiJuan Zhang; Daniel S H Kong; Joanna W K Ho; Hextan Y S Ngan; Dominic C W Chan; Annie N Y Cheung
Journal:  Am J Pathol       Date:  2010-04-22       Impact factor: 4.307

2.  Aberrantly activated pSTAT3-Ser727 in human endometrial cancer is suppressed by HO-3867, a novel STAT3 inhibitor.

Authors:  Brent J Tierney; Georgia A McCann; Shan Naidu; Kellie S Rath; Uksha Saini; Ross Wanner; Periannan Kuppusamy; Adrian Suarez; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2014-07-16       Impact factor: 5.482

3.  Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome.

Authors:  Michelle K Y Siu; Esther S Y Wong; Hoi Yan Chan; Hextan Y S Ngan; Kelvin Y K Chan; Annie N Y Cheung
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

Review 4.  LIF-STAT signaling and trophoblast biology.

Authors:  Pankaj Suman; Sudha Saryu Malhotra; Satish Kumar Gupta
Journal:  JAKSTAT       Date:  2013-06-27

5.  Downregulation of the gli transcription factors regulator Kif7 facilitates cell survival and migration of choriocarcinoma cells.

Authors:  Joanna Ho; Yanan Du; Oscar Gee-Wan Wong; Michelle K Y Siu; Karen K L Chan; Annie N Y Cheung
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

6.  Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia.

Authors:  Pengming Sun; Qibin Wu; Guanyu Ruan; Xiu Zheng; Yiyi Song; Jianfan Zhun; Lixiang Wu; Walter H Gotlieb
Journal:  Oncol Lett       Date:  2016-09-01       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.